Porcilis Pesti

Nazione: Unione Europea

Lingua: inglese

Fonte: EMA (European Medicines Agency)

Compra

Foglio illustrativo Foglio illustrativo (PIL)
06-10-2011
Scheda tecnica Scheda tecnica (SPC)
06-10-2011

Principio attivo:

Classical Swine Fever Virus (CSFV) -E2 subunit antigen

Commercializzato da:

Intervet International BV

Codice ATC:

QI09AD04

INN (Nome Internazionale):

Adjuvanted vaccine against classical swine fever

Gruppo terapeutico:

Pigs

Area terapeutica:

Immunologicals for suidae

Indicazioni terapeutiche:

Active immunisation of pigs from the age of 5 weeks onwards to prevent mortality and to reduce clinical signs of Classical Swine Fever, as well as to reduce infection with and excretion of CSF field virus.The onset of protection is 2 weeks.The duration of protection is 6 months.

Dettagli prodotto:

Revision: 12

Stato dell'autorizzazione:

Withdrawn

Data dell'autorizzazione:

2000-06-09

Foglio illustrativo

                                B. PACKAGE LEAFLET
14/17
PACKAGE LEAFLET
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE
MANUFACTURING
AUTHORISATION
HOLDER
RESPONSIBLE
FOR
BATCH
RELEASE, IF DIFFERENT
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis Pesti emulsion for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose of 2 ml contains:
120 Elisa Units Classical Swine Fever Virus-E2 subunit antigen
Liquid paraffin as adjuvant: 941.4 mg
4.
INDICATION(S)
_ _
Active immunisation of pigs from the age of 5 weeks onwards to prevent
mortality and to reduce clinical
signs of Classical Swine Fever, as well as to reduce infection with
and excretion of CSF field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months.
5.
CONTRAINDICATIONS
None
6.
ADVERSE REACTIONS
A local and in most cases transient swelling at the injection site may
occur up to 4 weeks after administration
of each dose of the vaccine. Transient hyperthermia may occur post the
second dose.
Abscesses may be observed at the injection site.
Since safety after giving both inoculations at the same site
has not been examined, it is advised to carry out the second
vaccination at a different site than the first
vaccination.
If you notice any serious side effects or other effects not mentioned
in this leaflet, please inform your
veterinary surgeon.
7.
TARGET SPECIES
Pigs
15/17
8.
DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION
Administer one dose (2 ml) by deep intramuscular injection in the neck
area behind the ear.
Vaccination scheme:
Basic vaccination: Inject one dose per pig followed by a second
injection 4 weeks after the first injection.
Re-vaccination: Every 6 months, using a single dose.
9.
ADVICE ON CORRECT ADMINISTRATION
Shake well before use.
Before use, allow the vaccine to reach room temperature.
Use sterile syringes and needles.
It is recommended to use a closed multiject vaccination system.
10.
WIT
                                
                                Leggi il documento completo
                                
                            

Scheda tecnica

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1/17
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis Pesti emulsion for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 2 ml contains:
ACTIVE SUBSTANCE:
Classical Swine Fever Virus (CSFV) -E2 subunit antigen: 120 Elisa
Units (EU)
ADJUVANT:
941.4 mg liquid paraffin
EXCIPIENTS:
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Emulsion for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of pigs from the age of 5 weeks onwards to prevent
mortality and to reduce clinical
signs of Classical Swine Fever, as well as to reduce infection with
and excretion of CSF field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months.
_ _
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Vaccinate only healthy animals.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO
ANIMALS
To the user:
2/17
This product contains mineral oil. Accidental injection/self injection
may result in severe pain and
swelling, particularly if injected into a joint or finger, and in rare
cases could result in the loss of the
affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt
medical advice even if only a very small
amount is injected and take the package leaflet with you.
If pain persists for more than 12 hours after medical examination,
seek medical advice again.
To the physician:
This product contains mineral oil. Even if small amounts have been
injected, accidental injection with this
product can cause intense swelling, which may, for example, result in
ischaemic necrosis and even the loss
of a digit. Expert, PROMPT, surgical attention is required and may
necessitate early incision and irrigation
of the injected area, especially where the
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo bulgaro 06-10-2011
Scheda tecnica Scheda tecnica bulgaro 06-10-2011
Foglio illustrativo Foglio illustrativo spagnolo 06-10-2011
Scheda tecnica Scheda tecnica spagnolo 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione spagnolo 26-02-2009
Foglio illustrativo Foglio illustrativo ceco 06-10-2011
Scheda tecnica Scheda tecnica ceco 06-10-2011
Foglio illustrativo Foglio illustrativo danese 06-10-2011
Scheda tecnica Scheda tecnica danese 06-10-2011
Foglio illustrativo Foglio illustrativo tedesco 06-10-2011
Scheda tecnica Scheda tecnica tedesco 06-10-2011
Foglio illustrativo Foglio illustrativo estone 06-10-2011
Scheda tecnica Scheda tecnica estone 06-10-2011
Foglio illustrativo Foglio illustrativo greco 06-10-2011
Scheda tecnica Scheda tecnica greco 06-10-2011
Foglio illustrativo Foglio illustrativo francese 06-10-2011
Scheda tecnica Scheda tecnica francese 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione francese 26-02-2009
Foglio illustrativo Foglio illustrativo italiano 06-10-2011
Scheda tecnica Scheda tecnica italiano 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione italiano 26-02-2009
Foglio illustrativo Foglio illustrativo lettone 06-10-2011
Scheda tecnica Scheda tecnica lettone 06-10-2011
Foglio illustrativo Foglio illustrativo lituano 06-10-2011
Scheda tecnica Scheda tecnica lituano 06-10-2011
Foglio illustrativo Foglio illustrativo ungherese 06-10-2011
Scheda tecnica Scheda tecnica ungherese 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione ungherese 26-02-2009
Foglio illustrativo Foglio illustrativo maltese 06-10-2011
Scheda tecnica Scheda tecnica maltese 06-10-2011
Foglio illustrativo Foglio illustrativo olandese 06-10-2011
Scheda tecnica Scheda tecnica olandese 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione olandese 26-02-2009
Foglio illustrativo Foglio illustrativo polacco 06-10-2011
Scheda tecnica Scheda tecnica polacco 06-10-2011
Foglio illustrativo Foglio illustrativo portoghese 06-10-2011
Scheda tecnica Scheda tecnica portoghese 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione portoghese 26-02-2009
Foglio illustrativo Foglio illustrativo rumeno 06-10-2011
Scheda tecnica Scheda tecnica rumeno 06-10-2011
Foglio illustrativo Foglio illustrativo slovacco 06-10-2011
Scheda tecnica Scheda tecnica slovacco 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione slovacco 26-02-2009
Foglio illustrativo Foglio illustrativo sloveno 06-10-2011
Scheda tecnica Scheda tecnica sloveno 06-10-2011
Foglio illustrativo Foglio illustrativo finlandese 06-10-2011
Scheda tecnica Scheda tecnica finlandese 06-10-2011
Relazione pubblica di valutazione Relazione pubblica di valutazione finlandese 26-02-2009
Foglio illustrativo Foglio illustrativo svedese 06-10-2011
Scheda tecnica Scheda tecnica svedese 06-10-2011
Foglio illustrativo Foglio illustrativo norvegese 06-10-2011
Scheda tecnica Scheda tecnica norvegese 06-10-2011
Foglio illustrativo Foglio illustrativo islandese 06-10-2011
Scheda tecnica Scheda tecnica islandese 06-10-2011

Visualizza cronologia documenti